Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015436031
Tue, 31.01.2023
CureVac
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio
The company holds one of broadest intellectual property portfolios in mRNA technology
TÜBINGEN, Germany/ BOSTON, USA – January [ … ]
Tue, 31.01.2023
CureVac
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio
The company holds one of broadest intellectual property portfolios in mRNA technology
TÜBINGEN, Germany/ BOSTON, USA – January [ … ]
Mon, 30.01.2023
CureVac
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu
COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 an [ … ]
Mon, 09.01.2023
CureVac
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023
Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on
April 1, 2023
TÜBINGEN, Germany/ BOSTON, USA – January 9, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company [ … ]
Fri, 06.01.2023
CureVac
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies
All candidates use CureVac’s advanced second-generation mRNA backbone optimized to achieve improved mRNA translation a [ … ]
Wed, 14.12.2022
CureVac
CureVac Members of Management Sell Shares to Cover Tax Obligations fromLong Term Incentive Program
TÜBINGEN, Germany/ Boston, USA – December 14, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Chief Execut [ … ]
Wed, 14.12.2022
CureVac
CureVac Members of Management Sell Shares to Cover Tax Obligations fromLong Term Incentive Program
TÜBINGEN, Germany/ Boston, USA – December 14, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Chief Execut [ … ]
Wed, 16.11.2022
CureVac
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK
Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023
Stre [ … ]
Wed, 16.11.2022
CureVac
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK
Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023
Stre [ … ]
Fri, 11.11.2022
CureVac
CureVac Presents Preliminary Data from Phase 1 Study Expansionof Oncology Candidate CV8102
Data confirm CV8102’s safety and ability to strongly mobilize the immune system against tumors
Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023
TÜBINGEN, Germany/ Boston, USA – November 11, 2022 - CureVac N.V. (Nasda [ … ]